$48.26
-0.25[-0.52%]
At close: Apr 16
$48.26
0[0.00%]
After Hours: 4:07PM EDT
Bristol-Myers Squibb
(NYSE:BMY)Latest News for Bristol-Myers Squibb Stock (NYSE:BMY)
Bristol-Myers Squibb Stock (NYSE: BMY)
Categories: All
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
- Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain MutationVandana Singh - Apr 8, 2024, 2:00PM
- Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal CancerBenzinga Newsdesk - Apr 8, 2024, 11:31AM
- Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other AntipsychoticsVandana Singh - Apr 8, 2024, 10:31AM
- Reported Saturday, Bristol Myers Squibb Presented New Interim Long-Term Efficacy Data From The EMERGENT-4 Trial Evaluating Karxt In Schizophrenia At The 2024 Annual Congress Of The SIRSBenzinga Newsdesk - Apr 8, 2024, 3:11AM
Friday, April 05, 2024
- FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerVandana Singh - Apr 5, 2024, 1:37PM
- At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard RegimensBenzinga Newsdesk - Apr 5, 2024, 9:09AM
- U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety ProfileBenzinga Newsdesk - Apr 5, 2024, 9:07AM
Thursday, April 04, 2024
Wednesday, April 03, 2024
- Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026Benzinga Newsdesk - Apr 3, 2024, 4:02PM
- Reported Earlier, European Commission Expands Approval Of Bristol Myers Squibb's Reblozyl® To Include First-Line Treatment Of Transfusion-Dependent Anemia In Adults With Lower-Risk Myelodysplastic SyndromesBenzinga Newsdesk - Apr 3, 2024, 2:31AM
Monday, April 01, 2024
Thursday, March 28, 2024
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint Of Progression-Free Survival For Patients With Pretreated KRASG12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung CancerBenzinga Newsdesk - Mar 28, 2024, 4:12PM
- Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12Benzinga Newsdesk - Mar 28, 2024, 4:02PM
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Mar 28, 2024, 1:35PM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
- Bristol Myers Squibb's Abecma CAR T Cell Therapy Approved In European Union In Earlier Lines For Triple-Class Exposed Relapsed And Refractory Multiple MyelomaBenzinga Newsdesk - Mar 20, 2024, 4:46PM
- GenScript Losses Shrink On Strong Growth For Cancer Cell TherapyThe Bamboo Works - Mar 20, 2024, 11:30AM
- Bristol Myers Squibb's Phase 3 Checkmate-9DW Trial Of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) As First-line Treatment For Advanced Hepatocellular Carcinoma Met Its Primary Endpoint Of Improved Overall Survival Compared To Sorafenib Or LenvatinibBenzinga Newsdesk - Mar 20, 2024, 7:01AM
Tuesday, March 19, 2024
Monday, March 18, 2024
- FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood CancerVandana Singh - Mar 18, 2024, 10:16AM
- Perspective Therapeutics Announces Collaboration Agreement Qith Bristol Myers Squibb To Evaluate [(212)Pb]VMT01 In Combination With Nivolumab In MC1R-Positive Metastatic Melanoma; Perspective Will Sponsor And Fund The Combination Study And Bristol Myers Squibb Will Provide Nivolumab For Use In The Study.Benzinga Newsdesk - Mar 18, 2024, 8:06AM
- Reported Saturday, FDA Advisory Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma For Triple-Class Exposed Multiple Myeloma In Earlier Lines Of TherapyBenzinga Newsdesk - Mar 18, 2024, 2:37AM
Friday, March 15, 2024
- Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers TherapyVandana Singh - Mar 15, 2024, 1:05PM
- What's Going On With Cancer Focused-Geron Stock On Friday?Vandana Singh - Mar 15, 2024, 11:29AM
- Bristol Myers Squibb's Breyanzi® Approved By U.S. FDA As The First And Only CAR T Cell Therapy For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic LymphomaBenzinga Newsdesk - Mar 15, 2024, 1:28AM
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Monday, March 11, 2024
Thursday, March 07, 2024
- Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan StanleyVandana Singh - Mar 7, 2024, 2:52PM
- FDA Says On March 6 Approved Nivolumab In Combination With Cisplatin & Gemcitabine; Approval For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial CarcinomaBenzinga Newsdesk - Mar 7, 2024, 11:57AM
- Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029Vandana Singh - Mar 7, 2024, 9:15AM
Tuesday, March 05, 2024
Monday, March 04, 2024
Wednesday, February 28, 2024
Friday, February 23, 2024
- Bristol-Myers Squibb Options Trading: A Deep Dive into Market SentimentBenzinga Insights - Feb 23, 2024, 2:45PM
- Bristol Myers Squibb Discloses Expiration of RayzeBio Tender Offer; Company Gets Positive CHMP Opinion For Reblozyl (luspatercept) For Treatment of Adults With Transfusion-Dependent Anemia Due To Low-To-Intermediate-Risk Myelodysplastic Syndromes (MDS)Benzinga Newsdesk - Feb 23, 2024, 7:02AM